oral glp-1 medications fda approved Approved: Orforglipron (Foundayo) — Drug • FDA for chronic weight management • Indicated for obesity and overweight with comorbidities • Oral, once-daily GLP-1 receptor agonist • First non-peptide FDA Approves Foundayo for Obesity
Description
Many patients who were initially nervous about injections find that the weekly pens are much easier to use than they expected
Your doctor will monitor you for any serious side effects, especially when you first start taking Foundayo
As trusted decision-makers in patient care, providers are the primary gatekeepers for access to new therapies
(2024) in different populations both exhibited significantly lower incidences of open-angle glaucoma in diabetic patient groups treated with GLP-1RAs medication compared with the control group
Are you eligible for GLP-1 treatments
